Enhancement of gemcitabine against pancreatic cancer by loading in mesoporous silica vesicles

Author:

Dai Jun-Tao,Zhang Yu,Li Heng-Chao,Deng Yong-Hui,Elzatahry Ahmed A.,Alghamdi Abdulaziz,Fu De-Liang,Jiang Yong-Jian,Zhao Dong-Yuan

Funder

National Natural Science Foundation of China

Shanghai Committee of Science and Technology

Shanghai Municipal Science and Technology Commission

National Youth Top-notch Talent Support Program

Qatar University

Deanship of Scientific Research

Publisher

Elsevier BV

Subject

General Chemistry

Reference34 articles.

1. Cancer statistics in China, 2015;Chen;CA: Cancer J. Clin.,2016

2. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States;Rahib;Cancer Res.,2014

3. Eligibility of metastatic pancreatic cancer patients for first-line palliative intent nab-paclitaxel plus gemcitabine versus FOLFIRINOX;Peixoto;Am. J. Clin. Oncol.,2015

4. Tumour-stroma interactions in pancreatic ductal adenocarcinoma: rationale and current evidence for new therapeutic strategies;Heinemann;Cancer Treat. Rev.,2014

5. Phase I trial and pharmacokinetics of gemcitabine in children with advanced solid tumors;Reid;J. Clin. Oncol.,2004

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3